Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: BIS Research | PRODUCT CODE: 1177478

Cover Image

PUBLISHER: BIS Research | PRODUCT CODE: 1177478

Global Prostate Cancer Testing Market - A Regional and Country Analysis: Focus on Test Type, Application, End User, and Region - Analysis and Forecast, 2022-2032

PUBLISHED:
PAGES: 223 Pages
DELIVERY TIME: 1-5 business days
SELECT AN OPTION
PDF and Excel (1-3 User License)
USD 5250
PDF and Excel (Global License)
USD 8100

Add to Cart

“Global Prostate Cancer Testing Market to Reach $21,306.9 Million by 2032.”

Global Prostate Cancer Testing Market Industry Overview

In 2021, the global prostate cancer testing market was valued at $5,246.9 million, and it is expected to reach $21,306.9 million by 2032, growing at a CAGR of 13.68% during the forecast period 2022-2032. The growth in the global prostate cancer testing market is expected to be driven by high investments in the field of cancer research and the rising prevalence of prostate cancer globally. In addition, the focus of business leaders is establishing a deep understanding to address the unmet needs in clinical research to understand the prostate cancer market.

Market Lifecycle Stage

The global prostate cancer testing market is in progressing phase. PSA screening or testing in a general population has increased the incidence of prostate cancer in recent decades. In addition, prostate cancer testing is essential in precision medicine because it assures the safe and successful use of tailored therapies. The majority of the companies in the global prostate cancer testing market provide biomarker tests that are urine, blood, and tissue-based, as well as testing services. Furthermore, applications of prostate cancer testing are primarily clinical and research.

Impact

One of the main reasons for the expansion of the prostate cancer testing market in the upcoming years is the rise in prostate cancer cases. Prostate cancer is the second most frequent disease diagnosed in men, and its frequency is rising across the globe. Prostate cancer is thought to be diagnosed in one million additional cases worldwide each year. Due to an aging population, growing urbanization, and accompanying lifestyle changes, the overall incidence of prostate cancer has increased over the past few decades.

Impact of COVID-19

During the coronavirus disease 2019 (COVID-19) pandemic, a number of disease models issued warnings about an excess of cancer fatalities brought on by missed cancer screenings as a result of the general population's quarantine and a lack of healthcare resources. The COVID-19 pandemic has had a negative impact on early diagnosis in the specific case of prostate cancer, the second most common cancer in men, by reducing participation in screening programs and on time from diagnostic testing to surgery/radiotherapy, which may translate into a worse prostate-cancer-specific death rate in the coming years. Additionally, in other areas, including Florida, state governments disallowed non-essential healthcare services.

Significant reductions in cancer screenings were seen in the early stages of the COVID-19 pandemic. According to a research paper published in January 2022 by the University of Florida, screenings for prostate cancer were reduced by 74%. Due to these screening figures, there may have been thousands more cancer deaths in the U.S. than were registered.

For instance, prostate-specific antigen (PSA) testing rates and the identification of several urological malignancies, including prostate cancer, have been found to be declining in significantly afflicted populations. Several Australian urologists worry that men with possibly curable prostate cancer may have missed their chance for a cure due to low screening test uptake during the lockdowns of 2020. According to a research paper published by BMC Urology in June 2022, a total of 4,048,099 PSA tests and 118,328 prostate biopsies were performed in Australia over the six years of data analysis. In the years 2019 and 2020, 68,429 prostate magnetic resonance imaging (MRI) were performed. Between 2015 and 2019, there were, on average, 19,573 prostate biopsies and 678,082 PSA testing performed per year.

Market Segmentation:

Segmentation 1: by Test Type

  • Pre-Biopsy Test
  • Biopsy
  • Post-Biopsy Test

Based on test type, the pre-biopsy test in the global prostate cancer testing market is expected to be dominated by the test type segment. This is due to the increasing popularity of prostate cancer testing and rising awareness related to prostate cancer testing.

Segmentation 2: by Application

  • Clinical
  • Research

Based on application, the global prostate cancer testing market is dominated by the clinical segment owing to the rising R&D activity focused on the development of prostate cancer testing. The diagnosis of prostate cancer has developed a new molecular-based diagnostics technology. To detect clinically relevant cancer upon diagnosis, several tools or therapeutic options are required to improve the patient's quality of life.

Segmentation 3: by End User

  • Cancer Research Institutes
  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Ambulatory Surgical Center (ASCs)
  • Others

Based on end user, the global prostate cancer testing market is dominated by the ambulatory surgical centers (ASCs) segment owing to their rise in number. They are dedicated to offering same-day surgical care, including testing and protective procedures. ASCs, which have a proven track record of providing high-quality treatment and successful patient outcomes, have altered the outpatient experience for millions of Americans by giving patients a more convenient option for hospital-based outpatient operations.

Segmentation 4: by Region

  • North America - U.S., and Canada
  • Europe - U.K., Germany, France, Italy, Spain, Netherlands and Rest-of-Europe
  • Asia-Pacific - Japan, China, India, South Korea, Australia, and Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, and Rest-of-Latin America
  • Rest-of-the-World

North America generated the highest revenue of $2,702.9 million in 2021, which is attributed to the several established diagnostics manufacturers in this region who are focusing on expanding their portfolios in prostate cancer testing and are collaborating with service providers and pharmaceutical giants to co-market prostate cancer testing solutions with its complementary precision medicine solutions. Moreover, the U.S. government is currently undertaking several initiatives to develop tests for cancer and provide funds to new start-ups in the cancer diagnostics field.

Recent Developments in the Global Prostate Cancer Testing Market

  • In September 2022, Veracyte, Inc. announced the publishing of data in the Journal of the National Cancer Institute to demonstrate the company's decipher prostate genomic classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease.
  • In August 2019, BioReference Laboratories, Inc. announced the selection by The IPA Association of America (TIPAAA) as its provider of laboratory services and to assist with data analytics for its members' patients. The agreement is designed to enhance patient care and offers collaborative health management tools to TIPAAA members, which includes more than 667 medical organizations in 39 states. The members can have convenient access to BioReference's comprehensive laboratory testing menu, including routine and specialty tests, as well as the 4Kscore for detecting aggressive prostate cancer.
  • In June 2021, Thermo Fisher Scientific announced submissions open for the Oncomine Clinical Research Grant program to support clinical research projects in oncology. The grant aims to provide funding for high-quality molecular profiling studies focusing on the impact of immune-based treatments for cancer patients.

Demand - Drivers and Limitations

The following are the demand drivers for the global prostate cancer testing market:

  • Rising Prevalence of Prostate Cancer Globally
  • Increasing Number of Prostate Cancer Screening and Testing
  • Government Initiatives Related to Prostate Cancer

The market is expected to face some limitations due to the following challenges:

  • Probability of False Positive Results of Prostate Cancer Testing
  • Clinical Gaps Related to Prostate Cancer Testing

How can this report add value to an organization?

  • Workflow/Innovation Strategy: The workflow segment helps the reader understand the two prostate cancer testing, i.e., pre-biopsy, biopsy, and post-biopsy, which further aid in diagnosis. Moreover, the study provides the reader with a detailed understanding of the different applications of prostate cancer testing in clinical and research applications.
  • Growth/Marketing Strategy: Prostate cancer testing is being used for both research and clinical application. Various companies are providing urine and blood, and tissue-based biomarkers that aid in the diagnosis, which is also the key strategy for market players to excel in the current prostate cancer testing market.
  • Competitive Strategy: Key players in the global prostate cancer testing market are analyzed and profiled in the study, including manufacturers who are involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global prostate cancer testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names in this market are:

  • Abbott.
  • Abcam plc.
  • Agilent Technologies, Inc.
  • Bio-Techne. (ExoDx)
  • Cleveland Diagnostics, Inc.
  • Danaher. (Beckman Coulter, Inc.)
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.)
  • H.U. Group Holdings, Inc. (Fujeribio)
  • mdxhealth.
  • Siemens Healthcare GmbH
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories.
  • OPKO Health, Inc. (GenPath)
  • Veracyte, Inc.

Companies that are not a part of the aforementioned pool have been well represented across different sections of the report (wherever applicable).

Product Code: BHP1296SA

Table of Contents

1 Markets

  • 1.1 Product Definition
    • 1.1.1 Inclusion and Exclusion Criteria
  • 1.2 Market Scope
    • 1.2.1 Scope of the Study
    • 1.2.2 Key Questions Answered in the Report
  • 1.3 Research Methodology
    • 1.3.1 Global Prostate Cancer Testing Market: Research Methodology
    • 1.3.2 Data Sources
      • 1.3.2.1 Primary Data Sources
      • 1.3.2.2 Secondary Data Sources
    • 1.3.3 Market Estimation Model
    • 1.3.4 Criteria for Company Profiling
  • 1.4 Market: Overview
    • 1.4.1 Market Definition
    • 1.4.2 Market Footprint and Growth Potential
    • 1.4.3 Future Potential
    • 1.4.4 COVID-19 Impact on Global Prostate Cancer Testing Market

2 Industry Analysis

  • 2.1 Overview
  • 2.2 Legal Requirements and Framework in the U.S.
    • 2.2.1 National Comprehensive Cancer Network (NCCN) Guidelines
    • 2.2.2 American Urological Association (AUA)
    • 2.2.3 American Cancer Society (ACS)
    • 2.2.4 U.S. Preventive Services Task Force (USPSTF)
  • 2.3 Legal Requirements and Framework in Europe
  • 2.4 Legal Requirements and Framework in Asia-Pacific
    • 2.4.1 China
  • 2.5 Patent Analysis
    • 2.5.1 Patent Filing Trend
    • 2.5.2 Patent Analysis (by Year)
    • 2.5.3 Patent Analysis (by Region)
    • 2.5.4 Patent Analysis (by Country)

3 Global Prostate Cancer Testing Market: Market Dynamics

  • 3.1 Overview
    • 3.1.1 Impact Analysis
  • 3.2 Market Drivers
    • 3.2.1 Rising Prevalence of Prostate Cancer Globally
      • 3.2.1.1 Disease Trend
      • 3.2.1.2 Increasing Number of Prostate Cancer Screening and Testing
      • 3.2.1.3 Government Initiatives Related to Prostate Cancer
    • 3.2.2 Market Restraints
      • 3.2.2.1 Probability of False Positive Results of Prostate Cancer Testing
      • 3.2.2.2 Clinical Gaps Related to Prostate Cancer Testing
    • 3.2.3 Market Opportunities
      • 3.2.3.1 New Treatment Therapy and Technique for Prostate Cancer

4 Global Prostate Cancer Testing Market: Competitive Landscape

  • 4.1 Overview
  • 4.2 Corporate Strategies
    • 4.2.1 Mergers and Acquisitions
    • 4.2.2 Synergistic Activities
    • 4.2.3 Business Expansions and Funding
  • 4.3 Business Strategies
    • 4.3.1 Product Launches and Approvals
    • 4.3.2 Publications
    • 4.3.3 Licenses and Agreements
    • 4.3.4 Other Activities
  • 4.4 Market Share Analysis

5 Global Prostate Cancer Testing Market (by Test Type), Value ($million), 2021-2032

  • 5.1 Overview
  • 5.2 Pre-biopsy Test
    • 5.2.1 Biomarker Test
      • 5.2.1.1 Blood-Based
      • 5.2.1.2 Urine-Based
    • 5.2.2 Imaging Test
  • 5.3 Biopsy
  • 5.4 Post-Biopsy Test
    • 5.4.1 Tissue-Based Biomarker Test

6 Global Prostate Cancer Testing Market (by Application), Value ($Million), 2021-2032

  • 6.1 Overview
  • 6.2 Clinical
  • 6.3 Research

7 Global Prostate Cancer Testing Market (by End User), Value ($Million), 2021-2032

  • 7.1 Overview
  • 7.2 Cancer Research Institutes
  • 7.3 Diagnostic Laboratories
  • 7.4 Hospitals and Clinics
  • 7.5 Ambulatory Surgical Centers (ASCs)
  • 7.6 Others

8 Global Prostate Cancer Testing Market (by Region), Value ($Million), 2021-2032

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 France
    • 8.3.3 U.K.
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Netherlands
    • 8.3.7 Rest-of-Europe
  • 8.4 Asia-Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest-of-Asia-Pacific (RoAPAC)
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest-of-Latin America
  • 8.6 Rest-of-the-World (RoW)

9 Company Profiles

  • 9.1 Overview
  • 9.2 Abbott.
    • 9.2.1 Company Overview
    • 9.2.2 Role of Abbott. in the Global Prostate Cancer Testing Market
    • 9.2.3 Key Competitors of the Company
    • 9.2.4 Financials
    • 9.2.5 Key Insights about the Financial Health of the Company
    • 9.2.6 Analyst Perspective
  • 9.3 Abcam plc.
    • 9.3.1 Company Overview
    • 9.3.2 Role of Abcam plc. in the Global Prostate Cancer Testing Market
    • 9.3.3 Key Customers of the Company
    • 9.3.4 Key Competitors of the Company
    • 9.3.5 Financials
    • 9.3.6 Analyst Perspective
  • 9.4 Agilent Technologies, Inc.
    • 9.4.1 Company Overview
    • 9.4.2 Role of Agilent Technologies, Inc. in the Global Prostate Cancer Testing Market
    • 9.4.3 Key Competitors of the Company
    • 9.4.4 Financials
    • 9.4.5 Analyst Perspective
  • 9.5 Bio-Techne. (ExoDx)
    • 9.5.1 Company Overview
    • 9.5.2 Role of Bio-Techne. (ExoDx) in the Global Prostate Cancer Testing Market
    • 9.5.3 Key Competitors of the Company
    • 9.5.4 Financials
    • 9.5.5 Key Insights about the Financial Health of the Company
    • 9.5.6 Corporate Strategies
    • 9.5.7 Business Strategies
    • 9.5.8 Analyst Perspective
  • 9.6 Cleveland Diagnostics, Inc.
    • 9.6.1 Company Overview
    • 9.6.2 Role of Cleveland Diagnostics, Inc. in the Global Prostate Cancer Testing Market
    • 9.6.3 Key Competitors of the Company
    • 9.6.4 Corporate Strategies
    • 9.6.5 Business Strategies
    • 9.6.6 Analyst Perspective
  • 9.7 Danaher. (Beckman Coulter, Inc.)
    • 9.7.1 Company Overview
    • 9.7.2 Role of Danaher. (Beckman Coulter, Inc.) in the Global Prostate Cancer Testing Market
    • 9.7.3 Key Competitors of the Company
    • 9.7.4 Financials
    • 9.7.5 Key Insights about the Financial Health of the Company
    • 9.7.6 Analyst Perspective
  • 9.8 Exact Sciences Corporation
    • 9.8.1 Company Overview
    • 9.8.2 Role of Exact Sciences Corporation in the Global Prostate Cancer Testing Market
    • 9.8.3 Key Customers of the Company
    • 9.8.4 Key Competitors of the Company
    • 9.8.5 Financials
    • 9.8.6 Key Insights about the Financial Health of the Company
    • 9.8.7 Corporate Strategies
    • 9.8.8 Business Strategies
    • 9.8.9 Analyst Perspective
  • 9.9 F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.)
    • 9.9.1 Company Overview
    • 9.9.2 Role of F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.) in the Global Prostate Cancer Testing Market
    • 9.9.3 Key Competitors of the Company
    • 9.9.4 Financials
    • 9.9.5 Key Insights about the Financial Health of the Company
    • 9.9.6 Corporate Strategies
    • 9.9.7 Business Strategies
    • 9.9.8 Analyst Perspective
  • 9.1 H.U. Group Holdings, Inc. (Fujeribio)
    • 9.10.1 Company Overview
    • 9.10.2 Role of H.U. Group Holdings, Inc. (Fujeribio) in the Global Prostate Cancer Testing Market
    • 9.10.3 Key Competitors of the Company
    • 9.10.4 Financials
    • 9.10.5 Analyst Perspective
  • 9.11 mdxhealth.
    • 9.11.1 Company Overview
    • 9.11.2 Role of mdxhealth. in the Global Prostate Cancer Testing Market
    • 9.11.3 Financials
    • 9.11.4 Key Insights about the Financial Health of the Company
    • 9.11.5 Corporate Strategies
      • 9.11.5.1 Mergers and Acquisitions
    • 9.11.6 Business Strategies
    • 9.11.7 Analyst Perspective
  • 9.12 Siemens Healthcare GmbH
    • 9.12.1 Company Overview
    • 9.12.2 Role of Siemens Healthcare GmbH in the Global Prostate Cancer Testing Market
    • 9.12.3 Key Competitors of the Company
    • 9.12.4 Financials
    • 9.12.5 Key Insights about the Financial Health of the Company
    • 9.12.6 Analyst Perspective
  • 9.13 Myriad Genetics, Inc.
    • 9.13.1 Company Overview
    • 9.13.2 Role of Myriad Genetics, Inc. in the Global Prostate Cancer Testing Market
    • 9.13.3 Key Competitors of the Company
    • 9.13.4 Corporate Strategies
    • 9.13.5 Business Strategies
    • 9.13.6 Financials
    • 9.13.7 Key Insights about the Financial Health of the Company
    • 9.13.8 Analyst Perspective
  • 9.14 NeoGenomics Laboratories.
    • 9.14.1 Company Overview
    • 9.14.2 Role of NeoGenomics Laboratories. in the Global Prostate Cancer Testing Market
    • 9.14.3 Key Competitors of the Company
    • 9.14.4 Financials
    • 9.14.5 Key Insights about the Financial Health of the Company
    • 9.14.6 Business Strategies
    • 9.14.7 Analyst Perspective
  • 9.15 OPKO Health, Inc. (GenPath)
    • 9.15.1 Company Overview
    • 9.15.2 Role of OPKO Health, Inc. (GenPath) in the Global Prostate Cancer Testing Market
    • 9.15.3 Key Customers of the Company
    • 9.15.4 Key Competitors of the Company
    • 9.15.5 Financials
    • 9.15.6 Key Insights about the Financial Health of the Company
    • 9.15.7 Corporate Strategies
    • 9.15.8 Business Strategies
    • 9.15.9 Analyst Perspective
  • 9.16 Veracyte, Inc.
    • 9.16.1 Company Overview
    • 9.16.2 Role of Veracyte, Inc. in the Global Prostate Cancer Testing Market
    • 9.16.3 Key Customers of the Company
    • 9.16.4 Key Competitors of the Company
    • 9.16.5 Financials
    • 9.16.6 Corporate Strategies
    • 9.16.7 Analyst Perspective
  • 9.17 Emerging Companies
    • 9.17.1 Exact imaging
    • 9.17.2 Proteomedix
    • 9.17.3 Gregor Diagnostics
Product Code: BHP1296SA

List of Figures

  • Figure 1: Tests Related to Prostate Cancer
  • Figure 2: Global Prostate Cancer Testing Market Segmentation
  • Figure 3: Share of Global Prostate Cancer Testing Market (by Test Type), $Million, 2021 and 2032
  • Figure 4: Share of Global Prostate Cancer Testing Market (by Application), $Million, 2021 and 2032
  • Figure 5: Share of Global Prostate Cancer Testing Market (by End User), $Million, 2021 and 2032
  • Figure 6: Global Prostate Cancer Testing Market Segmentation
  • Figure 7: Global Prostate Cancer Testing Market: Research Methodology
  • Figure 8: Primary Research Methodology
  • Figure 9: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 10: Top-Down Approach (Segment-Wise Analysis)
  • Figure 11: Workflow of Prostate Cancer Testing (NCCN Guidelines)
  • Figure 12: NCCN Guidelines for Prostate Cancer Propose Germline Testing for Patients
  • Figure 13: Year-Wise Analysis of Patents Related to Global Prostate Cancer Testing, January 2019-November 2022
  • Figure 14: Region-Wise Analysis of Patents Related to Prostate Cancer Testing, January 2019-November 2022
  • Figure 15: Country-Wise Analysis of Patents Related to Prostate Cancer Testing, January 2019-November 2022
  • Figure 16: Global Prostate Cancer Testing Market - Market Dynamics
  • Figure 17: Likert Scale
  • Figure 18: Impact Analysis of Market Drivers and Market Challenges on the Global Prostate Cancer Testing Market
  • Figure 19: Trend of New Cases and Death Rate Related to Prostate Cancer Market
  • Figure 20: Share of Key Developments, January 2019-November 2022
  • Figure 21: Share of Mergers and Acquisitions (by Company), January 2019-November 2022
  • Figure 22: Share of Synergistic Activities (by Company), January 2019-November 2022
  • Figure 23: Number of Business Expansions and Funding Activities (by Company), January 2019-November 2022
  • Figure 24: Number of Product Launches and Approvals (by Company), January 2019-November 2022
  • Figure 25: Share of Publications (by Company), January 2019-November 2022
  • Figure 26: Number of Licenses and Agreements (by Company), January 2019-November 2022
  • Figure 27: Number of Other Activities (by Company), January 2019-November 2022
  • Figure 28: Market Share Analysis of Global Prostate Cancer Testing Market (Pre-Biopsy Testing), 2021
  • Figure 29: Market Share Analysis of Global Prostate Cancer Testing Market (Post-Biopsy Tissue Testing), 2021
  • Figure 30: Global Prostate Cancer Testing Market (by Test Type)
  • Figure 31: Share of Global Prostate Cancer Testing Market (by Test Type), $Million, 2021 and 2032
  • Figure 32: Global Prostate Cancer Testing Market (Pre-Biopsy Test), $Million, 2021-2032
  • Figure 33: Phases of Biomarker
  • Figure 34: Classification of Biomarker
  • Figure 35: Biomarker Test: Prostate Cancer
  • Figure 36: Biomarker Testing: Goals
  • Figure 37: Global Prostate Cancer Testing Market (Biomarker Test), $Million, 2021-2032
  • Figure 38: Global Prostate Cancer Testing Market (Blood-Based), $Million, 2021-2032
  • Figure 39: Global Prostate Cancer Testing Market (Urine-Based), $Million, 2021-2032
  • Figure 40: Advantages of Imaging Test: Prostate Cancer
  • Figure 41: Imaging Test: Prostate Cancer
  • Figure 42: Advantages of mp-MRI
  • Figure 43: Global Prostate Cancer Testing Market (Imaging Test), $Million, 2021-2032
  • Figure 44: Uses of TRUS-Based Biopsy
  • Figure 45: Prostate Biopsy Methods
  • Figure 46: Global Prostate Cancer Testing Market (Biopsy), $Million, 2021-2032
  • Figure 47: Global Prostate Cancer Testing Market (Post-Biopsy Test), $Million, 2021-2032
  • Figure 48: Utility of Tissue-Based Biomarker in Prostate Cancer Management
  • Figure 49: Global Prostate Cancer Testing Market (Tissue-Based Biomarker Test), $Million, 2021-2032
  • Figure 50: Share of global Prostate Cancer Testing Market (by Application), $Million, 2021 and 2032
  • Figure 51: Global Prostate Cancer Testing Market (Clinical), $Million, 2021-2032
  • Figure 52: Global Prostate Cancer Testing Market (Research), $Million, 2021-2032
  • Figure 53: Global Prostate Cancer Testing Market (by End User)
  • Figure 54: Share of Global Prostate Cancer Testing Market (by End User), $Million, 2021 and 2032
  • Figure 55: Global Prostate Cancer Testing Market (Cancer Research Institute), $Million, 2021-2032
  • Figure 56: Global Prostate Cancer Testing Market (Diagnostic Laboratories), $Million, 2021-2032
  • Figure 57: Global Prostate Cancer Testing Market (Hospitals and Clinics), $Million, 2021-2032
  • Figure 58: Global Prostate Cancer Testing Market (Ambulatory Surgical Centers), $Million, 2021-2032
  • Figure 59: Global Prostate Cancer Testing Market (Others), $Million, 2021-2032
  • Figure 60: Global Prostate Cancer Testing Market Snapshot (by Region)
  • Figure 61: Global Prostate Cancer Testing Market (by Region), $Million, 2022-2032
  • Figure 62: North America Prostate Cancer Testing Market, $Million, 2022-2032
  • Figure 63: North America: Market Dynamics
  • Figure 64: North America Prostate Cancer Testing Market (by Country), $Million, 2021-2032
  • Figure 65: U.S. Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 66: U.S. Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 67: Canada Prostate Cancer Testing Market, $Million, 2022-2032
  • Figure 68: Canada Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 69: Europe Prostate Cancer Testing Market, $Million, 2022-2032
  • Figure 70: Europe: Market Dynamics
  • Figure 71: Europe Prostate Cancer Testing Market (by Country), $Million, 2021-2032
  • Figure 72: Germany Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 73: Germany Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 74: France Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 75: France Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 76: U.K. Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 77: U.K. Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 78: Italy Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 79: Italy Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 80: Spain Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 81: Spain Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 82: Netherlands Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 83: Netherlands Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 84: Rest-of-Europe Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 85: Rest-of-Europe Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 86: Asia-Pacific Prostate Cancer Testing Market, $Million, 2022-2032
  • Figure 87: Asia-Pacific: Market Dynamics
  • Figure 88: Asia-Pacific Prostate Cancer Testing Market (by Country), $Million, 2021-2032
  • Figure 89: China Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 90: China Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 91: Japan Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 92: Japan Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 93: India Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 94: India Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 95: Australia Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 96: Australia Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 97: South Korea Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 98: South Korea Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 99: Rest-of-Asia-Pacific Korea Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 100: Rest-of-Asia-Pacific Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 101: Latin America Prostate Cancer Testing Market, $Million, 2022-2032
  • Figure 102: Latin America: Market Dynamics
  • Figure 103: Latin America Prostate Cancer Testing Market (by Country), $Million, 2021-2032
  • Figure 104: Brazil Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 105: Brazil Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 106: Mexico Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 107: Mexico Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 108: Rest-of-Latin America Prostate Cancer Testing Market, $Million, 2021-2032
  • Figure 109: Rest-of-Latin America Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
  • Figure 110: Rest-of-the-World Prostate Cancer Testing Market, $Million, 2022-2032
  • Figure 111: Total Number of Companies Profiled
  • Figure 112: Abbott.: Product Portfolio
  • Figure 113: Abbott.: Overall Financials, $Million, 2019-2021
  • Figure 114: Abbott.: Revenue (by Segment), $Million, 2019-2021
  • Figure 115: Abbott.: Revenue (by Region), $Million, 2019-2021
  • Figure 116: Abbott.: R&D Expenditure, $Million, 2019-2021
  • Figure 117: Abcam plc.: Product Portfolio
  • Figure 118: Abcam plc.: Overall Financials, $Million, 2018-2020
  • Figure 119: Abcam plc.: Revenue (by Segment), $Million, 2019-2020
  • Figure 120: Abcam plc.: Revenue (by Region), $Million, 2018-2020
  • Figure 121: Abcam plc.: R&D Expenditure, $Million, 2019-2021
  • Figure 122: Agilent Technologies, Inc.: Product Portfolio
  • Figure 123: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 124: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 125: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 126: Agilent Technologies, Inc: R&D Expenditure, $Million, 2019-2021
  • Figure 127: Bio-Techne. (ExoDx): Product Portfolio
  • Figure 128: Bio-Techne. (ExoDx): Overall Financials, $Million, 2020-2022
  • Figure 129: Bio-Techne. (ExoDx): Revenue (by Segment), $Million, 2020-2022
  • Figure 130: Bio-Techne. (ExoDx): Revenue (by Region), $Million, 2020-2022
  • Figure 131: Bio-Techne. (ExoDx): R&D Expenditure, $Million, 2020-2022
  • Figure 132: Cleveland Diagnostics, Inc.: Product Portfolio
  • Figure 133: Danaher. (Beckman Coulter, Inc.): Product Portfolio
  • Figure 134: Danaher. (Beckman Coulter, Inc.): Overall Financials, $Million, 2019-2021
  • Figure 135: Danaher. (Beckman Coulter, Inc.): Revenue (by Segment), $Million, 2019-2021
  • Figure 136: Danaher. (Beckman Coulter, Inc.): Revenue (by Region), $Million, 2019-2021
  • Figure 137: Danaher. (Beckman Coulter, Inc.): R&D Expenditure, $Million, 2019-2021
  • Figure 138: Exact Sciences Corporation: Product Portfolio
  • Figure 139: Exact Sciences Corporation: Overall Financials, $Million, 2019-2021
  • Figure 140: Exact Sciences Corporation.: Revenue (by Segment), $Million, 2019-2021
  • Figure 141: Exact Sciences Corporation: Revenue (by Region), $Million, 2019-2021
  • Figure 142: Exact Sciences Corporation: R&D Expenditure, $Million, 2019-2021
  • Figure 143: F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): Product Portfolio
  • Figure 144: F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): Overall Financials, $Million, 2019-2021
  • Figure 145: F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): Revenue (by Segment), $Million, 2019-2021
  • Figure 146: F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): Revenue (by Region), $Million, 2019-2021
  • Figure 147: F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): R&D Expenditure, $Million, 2019-2021
  • Figure 148: H.U. Group Holdings, Inc. (Fujeribio): Product Portfolio
  • Figure 149: H.U. Group Holdings, Inc. (Fujeribio): Overall Financials, $Million, 2018-2020
  • Figure 150: H.U. Group Holdings, Inc. (Fujeribio): Revenue (by Segment), $Million, 2019-2021
  • Figure 151: H.U. Group Holdings, Inc. (Fujeribio): R&D Expenditure, $Million, 2018-2020
  • Figure 152: mdxhealth.: Product Portfolio
  • Figure 153: mdxhealth.: Overall Financials, $Million, 2019-2021
  • Figure 154: mdxhealth.: Revenue (by Segment), $Million, 2019-2021
  • Figure 155: mdxhealth.: R&D Expenditure, $Million, 2019-2021
  • Figure 156: Siemens Healthcare GmbH: Product Portfolio
  • Figure 157: Siemens Healthcare GmbH: Overall Financials, $Million, 2019-2021
  • Figure 158: Siemens Healthcare GmbH: Revenue (by Segment), $Million, 2019-2021
  • Figure 159: Siemens Healthcare GmbH: Revenue (by Region), $Million, 2019-2021
  • Figure 160: Siemens Healthcare GmbH: R&D Expenditure, $Million, 2019-2021
  • Figure 161: Myriad Genetics, Inc.: Product Portfolio
  • Figure 162: Myriad Genetics, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 163: Myriad Genetics, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 164: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 165: NeoGenomics Laboratories.: Product Portfolio
  • Figure 166: NeoGenomics Laboratories.: Overall Financials, $Million, 2019-2021
  • Figure 167: NeoGenomics Laboratories.: Revenue (by Segment), $Million, 2019-2021
  • Figure 168: NeoGenomics Laboratories.: R&D Expenditure, $Million, 2019-2021
  • Figure 169: OPKO Health, Inc. (GenPath): Product Portfolio
  • Figure 170: OPKO Health, Inc. (GenPath): Overall Financials, $Million, 2019-2021
  • Figure 171: OPKO Health, Inc. (GenPath): Revenue (by Segment), $Million, 2019-2021
  • Figure 172: OPKO Health, Inc. (GenPath): R&D Expenditure, $Million, 2019-2021
  • Figure 173: Veracyte, Inc.: Product Portfolio
  • Figure 174: Veracyte, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 175: Veracyte, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 176: Veracyte, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 177: Veracyte, Inc: R&D Expenditure, $Million, 2019-2021

List of Tables

  • Table 1: Impact Analysis of Market Drivers, Restraints, and Opportunities on the Global Prostate Cancer Testing Market
  • Table 2: Likert Scale
  • Table 3: Numerous Risk Categories for Clinically Localized Prostate Cancer
  • Table 4: Estimated Number of Deaths in 2018 and in 2040
  • Table 5: Recommendations Related to Prostate Cancer Screening
  • Table 6: Blood-Based Biomarkers for Prostate Cancer
  • Table 7: Guidance and Age Recommendations: Prostate Cancer
  • Table 8: Urine-Based Biomarkers for Prostate Cancer
  • Table 9: PCA3 Test Score
  • Table 10: Tissue-Based Biomarkers for Prostate Cancer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!